Pertuzumab biosimilar - Shanghai Henlius Biotech

Drug Profile

Pertuzumab biosimilar - Shanghai Henlius Biotech

Alternative Names: Anti-HER2 monoclonal antibody - Shanghai Henlius Biotech; HLX 11

Latest Information Update: 18 Jun 2015

Price : $50

At a glance

  • Originator Shanghai Henlius Biotech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Dimerisation inhibitors; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Breast cancer

Most Recent Events

  • 18 Jun 2015 Early research in Breast cancer in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top